D. Livermore

发表

Infections caused by Gram-positive bacteria: a review of the global challenge.

N. Woodford, D. Livermore, 2009, The Journal of infection.

Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London.

A. Charlett, D. Livermore, J. Turton, 2008, International journal of antimicrobial agents.

Discovery research: the scientific challenge of finding new antibiotics.

D. Livermore, 2011, The Journal of antimicrobial chemotherapy.

Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

M. Kaufmann, N. Woodford, D. Livermore, 2004, The Journal of antimicrobial chemotherapy.

A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus.

D. Livermore, S. Neidle, M. Gunaratnam, 2013, International journal of antimicrobial agents.

In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.

N. Woodford, D. Livermore, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

N. Woodford, D. Livermore, D. Paterson, 2010, The Lancet. Infectious diseases.

Bacterial resistance: origins, epidemiology, and impact.

D. Livermore, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study.

D. Livermore, M. Toleman, T. Walsh, 2011, The Lancet. Infectious diseases.

beta-Lactamases in laboratory and clinical resistance

D. Livermore, 1995, Clinical microbiology reviews.

Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp.

N. Woodford, D. Livermore, J. Turton, 2006, International journal of antimicrobial agents.

Trends among pathogens reported as causing bacteraemia in England, 2004-2008.

B. Cookson, D. Livermore, E. Sheridan, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing

Lisa C. Crossman, N. J. Saunders, S. Mwaigwisya, 2017, The Journal of antimicrobial chemotherapy.

Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013.

N Woodford, R Canton, A. Friedrich, 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection

Richard M Leggett, Justin O'Grady, Daniel J Turner, 2019, Nature Biotechnology.

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Hui Wang, Robert A Bonomo, Neil Woodford, 2013, The Lancet. Infectious diseases.

Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System

N. Woodford, D. Livermore, G. Bou, 2011, Antimicrobial Agents and Chemotherapy.

Are SHV β-Lactamases Universal in Klebsiella pneumoniae?

D. Livermore, G. Babini, 2000, Antimicrobial Agents and Chemotherapy.

The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter

Neil Woodford, N. Woodford, D. Livermore, 2006 .

Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis

R C George, D. Livermore, R. George, 2000, BMJ : British Medical Journal.

The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.

N. Woodford, D. Livermore, 2006, Trends in microbiology.

UK General Practice Research Database infections: retrospective cohort study with the complications of common respiratory tract Protective effect of antibiotics against serious

I. Petersen, D. Livermore, A. Johnson, 2008 .

Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database

I. Petersen, D. Livermore, G. Duckworth, 2008 .

Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database

Anne M Johnson, I. Petersen, D. Livermore, 2007, BMJ : British Medical Journal.

Surveillance of antimicrobial resistance

D. Livermore, A. MacGowan, M. Wale, 1998, BMJ.

Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007.

B. Cookson, D. Livermore, M. Ellington, 2010, The Journal of antimicrobial chemotherapy.

Fourteen years in resistance.

D. Livermore, David M Livermore, 2012, International journal of antimicrobial agents.

Carbapenem antibiotics for serious infections

D. Livermore, P. Hawkey, 2012, BMJ : British Medical Journal.

The emerging NDM carbapenemases.

D. Livermore, P. Nordmann, L. Poirel, 2011, Trends in microbiology.

Distribution of β-lactamases in carbapenem-non-susceptible Acinetobacter baumannii in Riyadh, Saudi Arabia.

D. Livermore, A. Shibl, Mohamed S Ali, 2014, Journal of global antimicrobial resistance.

IMP-4, a Novel Metallo-β-Lactamase from Nosocomial Acinetobacter spp. Collected in Hong Kong between 1994 and 1998

N. Woodford, D. Livermore, M. Afzal-Shah, 2001, Antimicrobial Agents and Chemotherapy.

Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumannii

N. Woodford, D. Livermore, M. Afzal-Shah, 2001, Antimicrobial Agents and Chemotherapy.

Occurrence of OXA-58-Like Carbapenemases in Acinetobacter spp. Collected over 10 Years in Three Continents

N. Woodford, D. Livermore, M. Afzal-Shah, 2006, Antimicrobial Agents and Chemotherapy.

Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea.

N. Woodford, D. Livermore, Seungok Lee, 2009, International journal of antimicrobial agents.

Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase.

N. Woodford, D. Livermore, M. Doumith, 2009, The Journal of antimicrobial chemotherapy.

Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy.

N. Loman, M. Pallen, N. Woodford, 2011, The Journal of antimicrobial chemotherapy.

Introduction: the challenge of multiresistance.

D. Livermore, 2007, International journal of antimicrobial agents.

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D &bgr;-lactamases

N. Woodford, D. Livermore, S. Mushtaq, 2017, The Journal of antimicrobial chemotherapy.

NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases.

N. Woodford, D. Livermore, K. Hopkins, 2014, The Journal of antimicrobial chemotherapy.

Early (2008-2010) hospital outbreak of Klebsiella pneumoniae producing OXA-48 carbapenemase in the UK.

N. Woodford, D. Livermore, A. Holmes, 2013, International journal of antimicrobial agents.

Balkan NDM-1: escape or transplant?

N. Woodford, D. Livermore, M. Toleman, 2011, The Lancet. Infectious diseases.

Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases.

N. Woodford, D. Livermore, R. Pike, 2011, The Journal of antimicrobial chemotherapy.

Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance.

N. Woodford, D. Livermore, J. Turton, 2011, FEMS microbiology reviews.

Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media.

N. Woodford, D. Livermore, A. Hussain, 2011, The Journal of antimicrobial chemotherapy.

OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014

N. Woodford, D. Livermore, K. Hopkins, 2017, The Journal of antimicrobial chemotherapy.

Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.

N. Woodford, D. Livermore, M. Ellington, 2009, The Journal of antimicrobial chemotherapy.

The need for new antibiotics.

D. Livermore, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Detection of β-lactamase-mediated resistance

D. Livermore, Derek F. J. Brown, 2001 .

Antibiotic resistance among enterococci causing endocarditis in the UK: analysis of isolates referred to a reference laboratory

N. Woodford, D. Livermore, A. Johnson, 1998, BMJ.

Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.

N. Woodford, D. Livermore, G. Hasçelik, 2008, International journal of antimicrobial agents.

CTX-M: changing the face of ESBLs in the UK.

D. Livermore, P. Hawkey, 2005, The Journal of antimicrobial chemotherapy.

Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital.

D. Livermore, L. Hall, D. Gur, 1992, The Journal of antimicrobial chemotherapy.

OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa

D. Livermore, M. Akova, H. Akalın, 1993, Antimicrobial Agents and Chemotherapy.

OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa

D. Livermore, L. Hall, D. Gur, 1993, Antimicrobial agents and chemotherapy.

OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain

D. Livermore, L. Hall, D. Gur, 1997, Antimicrobial agents and chemotherapy.

OXA-16, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, from Two Pseudomonas aeruginosa Isolates

D. Livermore, L. Hall, D. Gur, 1998, Antimicrobial Agents and Chemotherapy.

Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units.

T. Pitt, D. Livermore, H. Aucken, 1998, The Journal of antimicrobial chemotherapy.

OXA-17, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, Isolated from Pseudomonas aeruginosa

D. Livermore, L. Hall, D. Gur, 1999, Antimicrobial Agents and Chemotherapy.

Detection of Extended-Spectrum β-Lactamases in Klebsiellae with the Oxoid Combination Disk Method

D. Livermore, M. Warner, M. Carter, 2000, Journal of Clinical Microbiology.

National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa.

D. Livermore, D M Livermore, H Y Chen, 1995, The Journal of antimicrobial chemotherapy.

Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.

D. Livermore, S. Mushtaq, C. Horner, 2019, The Journal of antimicrobial chemotherapy.

Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06.

D. Livermore, R. Reynolds, R. Hope, 2008, The Journal of antimicrobial chemotherapy.

The threat from the pink corner

D. Livermore, 2003, Annals of medicine.

Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.

D. Livermore, H. Chen, 1997, The Journal of antimicrobial chemotherapy.

Sensitivity testing of ciprofloxacin for Pseudomonas aeruginosa.

D. Livermore, I. B. Ibrahim-Elmagboul, 1997, The Journal of antimicrobial chemotherapy.

Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing.

D. Livermore, D. James, A. Johnson, 2000, The Journal of antimicrobial chemotherapy.

Detection of PSE-2 beta-lactamase in enterobacteria

J. Williams, D. Livermore, J. Maskell, 1984, Antimicrobial Agents and Chemotherapy.

Characterization of NPS-1, a novel plasmid-mediated beta-lactamase, from two Pseudomonas aeruginosa isolates

D. Livermore, C. Jones, 1986, Antimicrobial Agents and Chemotherapy.

LXA-1: a new plasmid-mediated β-lactamase giving low-level resistance

G. Jacoby, D. Livermore, Youjun Yang, 1988 .

Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates

D. Livermore, Youjun Yang, Y. Yang, 1990, Antimicrobial Agents and Chemotherapy.

Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study.

J. O’Grady, V. Gant, D. Livermore, 2022, Thorax.

Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study

J. O’Grady, V. Gant, D. Livermore, 2020, Thorax.

Regional variation in ampicillin and trimethoprim resistance in Escherichia coli in England from 1990 to 1997, in relation to antibacterial prescribing.

D. Livermore, D. Northcott, R. George, 2000, The Journal of antimicrobial chemotherapy.

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

D. Livermore, I. Gyssens, C. Viscoli, 2013, Haematologica.

Mechanisms of Resistance to Cephalosporin Antibiotics

D. Livermore, 2012, Drugs.

Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, Colombia

M. Kaufmann, N. Woodford, D. Livermore, 2004, Journal of Clinical Microbiology.

Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe.

T. Pitt, D. Livermore, A. Vatopoulos, 1990, Journal of Antimicrobial Chemotherapy.

Outbreak of Infections Caused by Pseudomonas aeruginosa Producing VIM-1 Carbapenemase in Greece

N. Woodford, D. Livermore, S. Pournaras, 2000, Journal of Clinical Microbiology.

bla VIM-2 Cassette-Containing Novel Integrons in Metallo-β-Lactamase-Producing Pseudomonas aeruginosa and Pseudomonas putida Isolates Disseminated in a Korean Hospital

D. Livermore, D. Yong, Y. Chong, 2002, Antimicrobial Agents and Chemotherapy.

Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New blaIMP Allele, blaIMP-7

Richard A. Moore, T. Louie, N. Woodford, 2002, Antimicrobial Agents and Chemotherapy.

IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK.

N. Woodford, D. Livermore, P. Chadwick, 2002, The Journal of antimicrobial chemotherapy.

New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080.

N. Woodford, D. Livermore, M. Doumith, 2016, The Journal of antimicrobial chemotherapy.

Can better prescribing turn the tide of resistance?

D. Livermore, 2004, Nature Reviews Microbiology.

Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT

D. Thickett, D. Livermore, E. Chilvers, 2021, Efficacy and Mechanism Evaluation.

Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.

D. Thickett, D. Livermore, W. Fraser, 2020, JAMA.

Antimicrobial Resistance in Bacteria, C.F. Amábile-Cuevas (Ed.). Horizon Bioscience, Wymondham, UK (2007), 201 pp., ISBN: 978-1-904933-24-3

D. Livermore, 2007 .

Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy.

N. Woodford, D. Livermore, M. Doumith, 2008, Journal of Antimicrobial Chemotherapy.

Outbreak of Pseudomonas aeruginosa Infections with PER-1 Extended-Spectrum β-Lactamase in Warsaw, Poland: Further Evidence for an International Clonal Complex

D. Livermore, W. Hryniewicz, M. Gniadkowski, 2007, Journal of Clinical Microbiology.

Activity of the oxazolidinones AZD2563 and linezolid against Corynebacterium jeikeium and other Corynebacterium spp.

D. Livermore, A. Johnson, M. Warner, 2003, The Journal of antimicrobial chemotherapy.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model

D. Livermore, J. McCauley, S. Bhavnani, 2017, Antimicrobial Agents and Chemotherapy.

Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.

G. Jackson, D. Livermore, G. Daikos, 1990, The Journal of infectious diseases.

The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients

D. Livermore, I. Gyssens, W. Kern, 2013, Haematologica.

Linezolid in vitro: mechanism and antibacterial spectrum.

D. Livermore, 2003, The Journal of antimicrobial chemotherapy.

Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network.

D. Livermore, M. Jones, D. Sahm, 1999, The Journal of antimicrobial chemotherapy.

Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment.

G. Scott, N. Woodford, D. Livermore, 2010, International journal of antimicrobial agents.

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.

D. Livermore, S. Mushtaq, Yigong Ge, 2010, The Journal of antimicrobial chemotherapy.

European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia

D. Livermore, I. Gyssens, C. Viscoli, 2013, Haematologica.

Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants

N. Woodford, D. Livermore, M. Warner, 2015, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated?

D. Livermore, A. Johnson, G. Tillotson, 2001, The Journal of hospital infection.

Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.

D. Livermore, R. George, A. Johnson, 2001, The Journal of antimicrobial chemotherapy.

Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.

N. Woodford, D. Livermore, M. Warner, 2015, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Cephalosporin RWJ-54428 (MC-02479) against Multidrug-Resistant Gram-Positive Cocci

D. Livermore, M. Warner, Alan P. Johnson, 2002, Antimicrobial Agents and Chemotherapy.

Effects of CO2 and pH on inhibition of TEM-1 and other beta-lactamases by penicillanic acid sulfones

D. Livermore, J. Corkill, 1992, Antimicrobial Agents and Chemotherapy.

Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993.

D. Livermore, M. Yuan, H. Chen, 1995, Journal of medical microbiology.

Effect of inoculum size on the in-vitro susceptibility to β-lactam antibiotics of Moraxella catarrhalis isolates of different β-lactamase types

D. Livermore, S. Yeo, 1994 .

Kinetics and significance of the activity of the Sabath and Abrahams' beta-lactamase of Pseudomonas aeruginosa against cefotaxime and cefsulodin.

D. Livermore, 1983, The Journal of antimicrobial chemotherapy.

Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction

D. Livermore, P. Stephens, L. Hall, 2001, The Lancet.

Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients.

S. North, N. Woodford, D. Livermore, 2010, The Journal of antimicrobial chemotherapy.

Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?

N. Woodford, D. Livermore, R. Reynolds, 2013, The Journal of antimicrobial chemotherapy.

Bacterial resistance to carbapenems.

D. Livermore, 1995, Advances in experimental medicine and biology.

Antibiotic uptake and transport by bacteria.

D. Livermore, 1990, Scandinavian journal of infectious diseases. Supplementum.

Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus.

D. Livermore, M. Warner, A. Wilson, 2006, Journal of Antimicrobial Chemotherapy.

In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia

F. Baquero, R. Zbinden, H. Endtz, 2001, Antimicrobial Agents and Chemotherapy.

Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07.

D. Livermore, A. MacGowan, M. Ellington, 2012, The Journal of antimicrobial chemotherapy.

Doripenem: antimicrobial profile and clinical potential.

D. Livermore, 2009, Diagnostic microbiology and infectious disease.

Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential

D. Livermore, S. Mushtaq, Yigong Ge, 2004, Antimicrobial Agents and Chemotherapy.

Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?

J. Quinn, V. Yu, Y. Carmeli, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989.

D. Livermore, L. Hall, P. Seetulsingh, 1991, The Journal of antimicrobial chemotherapy.

Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures.

C. Mcnulty, D. Livermore, A. Holmes, 2015, The Journal of antimicrobial chemotherapy.

The zeitgeist of resistance.

D. Livermore, 2007, The Journal of antimicrobial chemotherapy.

Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002

D. Livermore, K. Fenton, Alan P. Johnson, 2003, The Lancet.

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.

A. Friedrich, Y. Carmeli, D. Aanensen, 2017, The Lancet. Infectious diseases.

Nalidixic acid-susceptible, ciprofloxacin-resistant Neisseria gonorrhoeae strain in the UK.

D. Livermore, C. Ison, P. Ragunathan, 2005, The Journal of antimicrobial chemotherapy.

Multiresistant serotype O 12 Pseudomonas aeruginosa: evidence for a common strain in Europe

T. Pitt, D. Livermore, A. Vatopoulos, 1989, Epidemiology and Infection.

Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011.

D. Livermore, C. Lowndes, K. Town, 2013, The Lancet. Infectious diseases.

Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.

N. Woodford, D. Livermore, A. Kearns, 2015, The Journal of antimicrobial chemotherapy.

Effects of low temperature and high salt on the activity of the novel carbapenem PZ-601 (SMP-601) against methicillin-resistant Staphylococcus aureus.

D. Livermore, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

D. Livermore, M. Warner, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

Leading article Acquired carbapenemases

D. Livermore, 1997 .

Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.

D. Livermore, G. Duckworth, R. George, 2005, International journal of antimicrobial agents.

Do β-lactamases trap cephalosporins?

D. Livermore, 1985 .

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.

N. Woodford, D. Livermore, M. Ellington, 2020, The Journal of antimicrobial chemotherapy.

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16

N. Woodford, D. Livermore, K. Hopkins, 2018, The Journal of antimicrobial chemotherapy.

In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase

N. Woodford, D. Livermore, M. Warner, 2015, Antimicrobial Agents and Chemotherapy.

OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline

D. Livermore, W. Hope, S. Boyd, 2022, Antimicrobial agents and chemotherapy.

Title: Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: a randomized clinical trial Subtitle: The EME-TIPAC study

D. Thickett, D. Livermore, E. Chilvers, 2020 .

University of Birmingham Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis

D. Thickett, D. Livermore, E. Chilvers, 2020 .

Replacement of Enterococcus faecalis by Enterococcus faecium as the predominant enterococcus in UK bacteraemias

N. Woodford, D. Livermore, R. Reynolds, 2021, JAC-antimicrobial resistance.

Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

D. Livermore, M. Akova, Y. Yang, 1990, The Journal of antimicrobial chemotherapy.

TITLE Rapid and Point of Care Testing ( POCT ) in Respiratory Tract Infections : An Antibiotic Guardian ?

V. Gant, D. Livermore, V. Enne, 2020 .

Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis" by Horita et al.

D. Livermore, T. Calandra, I. Gyssens, 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients.

D. Livermore, C. Viscoli, M. Akova, 2014, The Journal of infection.

High-level beta-lactam resistance in strains of Streptococcus pneumoniae isolated in the UK.

N. Woodford, D. Livermore, A. Johnson, 1998, The Journal of antimicrobial chemotherapy.

Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?

D. Livermore, A. MacGowan, C. Horner, 2018, The Journal of antimicrobial chemotherapy.

Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001-2004.

R. Pebody, D. Livermore, R. George, 2005, Journal of Antimicrobial Chemotherapy.

Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases.

N. Woodford, D. Livermore, M. Ellington, 2006, The Journal of antimicrobial chemotherapy.

Extended-spectrum β-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study.

N. Woodford, D. Livermore, K. Hopkins, 2019, The Lancet. Infectious diseases.

Temocillin revived.

D. Livermore, P. Tulkens, 2009, The Journal of antimicrobial chemotherapy.

Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England.

N. Woodford, D. Livermore, E. Fagan, 2006, The Journal of antimicrobial chemotherapy.

Dissociation of surface properties and ” intrinsic ” resistance top lactams in Pseudornonas aeruginosa

T. Pitt, D. Livermore, 2008 .

Dissociation of surface properties and "intrinsic" resistance to beta lactams in Pseudomonas aeruginosa.

T. Pitt, D. Livermore, 1986, Journal of medical microbiology.

Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams.

D. Livermore, H. Villar, F. Danel, 1997, The Journal of antimicrobial chemotherapy.

Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

D. Livermore, 2000, The Journal of antimicrobial chemotherapy.

Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998.

D. Livermore, G. Babini, 2000, The Journal of antimicrobial chemotherapy.

Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa

D. Livermore, D. Gür, H. Akalın, 1995 .

Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom.

M. Kaufmann, N. Woodford, D. Livermore, 2008, The Journal of antimicrobial chemotherapy.

Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa.

D. Livermore, H. Akalın, L. Hall, 1995, The Journal of antimicrobial chemotherapy.

β-Lactamase Lability and Inducer Power of Newer β-Lactam Antibiotics in Relation to Their Activity Against β-Lactamase-Inducibility Mutants of Pseudomonas aeruginosa

D. Livermore, Youjun Yang, 1987 .

Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa.

D. Livermore, Y. Yang, 1987, The Journal of infectious diseases.

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.

D. Livermore, A. Johnson, M. Warner, 2004, International journal of antimicrobial agents.

A one-year survey of Neisseria gonorrhoeae isolated from patients attending an east London genitourinary medicine clinic: antibiotic susceptibility patterns and patients' characteristics.

D. Livermore, C. Ison, H. Y. Chen, 1995, Genitourinary medicine.

Homogeneity of antimicrobial policy, yet heterogeneity of antimicrobial resistance: antimicrobial non-susceptibility among 108 717 clinical isolates from primary, secondary and tertiary care patients in London

D. Livermore, M. Gharbi, A. Holmes, 2014, The Journal of antimicrobial chemotherapy.

Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man.

D. Livermore, L. Hall, D. Bean, 2005, The Journal of antimicrobial chemotherapy.

Efflux Pumps, OprD Porin, AmpC β-Lactamase, and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

N. Woodford, D. Livermore, J. Turton, 2010, Antimicrobial Agents and Chemotherapy.

Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.

D. Livermore, M. Warner, S. Mushtaq, 2005, The Journal of antimicrobial chemotherapy.

Mutation frequency in antibiotic-resistant and -susceptible isolates of Streptococcus pneumoniae.

D. Livermore, R. George, C. Sheppard, 2010, International journal of antimicrobial agents.

A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study

S. Conti, A. Charlett, N. Woodford, 2017, Antibiotics.

Population structure of Escherichia coli causing bacteraemia in the UK and Ireland between 2001 and 2010.

J. Wain, N. Woodford, D. Livermore, 2016, The Journal of antimicrobial chemotherapy.

Genetic environment of metallo-β-lactamase genes in Pseudomonas aeruginosa isolates from the UK.

N. Woodford, D. Livermore, K. Hopkins, 2015, The Journal of antimicrobial chemotherapy.

Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa

N. Woodford, D. Livermore, J. Turton, 2015 .

Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.

N. Verlander, D. Livermore, S. Hopkins, 2013, The Journal of antimicrobial chemotherapy.

Variation in the genetic environments of bla(CTX-M-15) in Escherichia coli from the faeces of travellers returning to the United Kingdom.

Rajesh Patel, N. Woodford, D. Livermore, 2011, The Journal of antimicrobial chemotherapy.

Cephalosporin resistance mechanisms in Escherichia coli isolated from raw chicken imported into the UK.

N. Woodford, D. Livermore, N. Murphy, 2010, The Journal of antimicrobial chemotherapy.

Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.

D. Livermore, D. James, M. Warner, 2010, The Journal of antimicrobial chemotherapy.

Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing method.

D. Livermore, M. Warner, R. Hope, 2010, The Journal of antimicrobial chemotherapy.

Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli.

N. Woodford, D. Livermore, A. Loughrey, 2009, The Journal of antimicrobial chemotherapy.

Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.

D. Livermore, D. James, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

First isolation of a CTX-M-3 β-lactamase producer in the United Kingdom

N. Woodford, D. Livermore, T. Winstanley, 2004 .

Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method.

D. Livermore, D. James, A. Johnson, 2004, The Journal of antimicrobial chemotherapy.

False-positive extended-spectrum β-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 β-lactamase

D. Livermore, R. Reynolds, M. Warner, 2004 .

Effect of inoculum size on the in-vitro susceptibility to beta-lactam antibiotics of Moraxella catarrhalis isolates of different beta-lactamase types.

D. Livermore, S. Yeo, 1994, Journal of medical microbiology.

Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK.

N. Woodford, D. Livermore, D. James, 2002, Journal of medical microbiology.

Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999

D. Livermore, R. George, D. James, 2002, Emerging infectious diseases.

Mechanisms of chloramphenicol resistance in Haemophilus influenzae in the United Kingdom.

D. Livermore, M. Powell, Mair Powell, 1988, Journal of medical microbiology.

Performance of the Oxoid M.I.C.Evaluator™ Strips compared with the Etest® assay and BSAC agar dilution

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Penicillin-binding proteins, porins and outer-membrane permeability of carbenicillin-resistant and -susceptible strains of Pseudomonas aeruginosa.

D. Livermore, 1984, Journal of medical microbiology.

Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.

N. Woodford, D. Livermore, S. Mushtaq, 2021, The Journal of antimicrobial chemotherapy.

Dominance of international 'high-risk clones' among metallo-β-lactamase-producing Pseudomonas aeruginosa in the UK.

N. Woodford, D. Livermore, K. Hopkins, 2015, The Journal of antimicrobial chemotherapy.

Complete Nucleotide Sequences of Plasmids pEK204, pEK499, and pEK516, Encoding CTX-M Enzymes in Three Major Escherichia coli Lineages from the United Kingdom, All Belonging to the International O25:H4-ST131 Clone

N. Woodford, D. Livermore, A. Carattoli, 2009, Antimicrobial Agents and Chemotherapy.

PENICILLIN-BINDING PROTEINS, PORINS A N D OUTER-MEMBRANE PERMEABILITY OF CARBENICILLIN- RESISTANT AND -SUSCEPTIBLE STRAINS OF PSEUDOMONAS AERUGINOSA

D. Livermore, 2008 .

Invalidity for Pseudomonas aeruginosa of an accepted model of bacterial permeability to beta-lactam antibiotics

D. Livermore, K. Davy, 1991, Antimicrobial Agents and Chemotherapy.

Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles

N. Woodford, D. Livermore, K. Hopkins, 2017, The Journal of antimicrobial chemotherapy.

AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications

Robert Wenger, D. Livermore, C. Strahm, 2022, BMC Infectious Diseases.

Prevalence of ciprofloxacin‐resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK

D. Livermore, R. Mills, M. Rochester, 2015, BJU international.

AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii.

J. Quinn, N. Woodford, D. Livermore, 2010, The Journal of antimicrobial chemotherapy.

Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum beta-lactamases in the UK.

N. Woodford, D. Livermore, K. Nye, 2008, The Journal of antimicrobial chemotherapy.

β-Lactamases of Pseudomonas aeruginosa

D. Livermore, 1991 .

Importation of multidrug-resistant Acinetobacter spp infections with casualties from Iraq.

T. Pitt, D. Livermore, J. Turton, 2006, Lancet. Infectious Diseases (Print).

Tigecycline: what is it, and where should it be used?

D. Livermore, 2005, The Journal of antimicrobial chemotherapy.

Defining an extended‐spectrum β‐lactamase

D. Livermore, 2008 .

Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999.

D. Livermore, A. Johnson, M. Warner, 2000, The Journal of antimicrobial chemotherapy.

P1348 Prevalence of an epidemic ESBL-producing Escherichia coli strain in LTCFs in Belfast

N. Woodford, D. Livermore, M. Warner, 2007 .

UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone.

M. Kaufmann, N. Woodford, D. Livermore, 2008, The Journal of antimicrobial chemotherapy.

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

N. Woodford, D. Livermore, D. James, 2002, The Journal of antimicrobial chemotherapy.

Efficacies of calcium–EDTA in combination with imipenem in a murine model of sepsis caused by Escherichia coli with NDM-1 β-lactamase

N. Woodford, D. Livermore, K. Tateda, 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis.

N. Woodford, D. Livermore, S. Hopkins, 2011, The Journal of antimicrobial chemotherapy.

Detection of beta-lactamase-mediated resistance.

D. Livermore, D. Brown, 2001, The Journal of antimicrobial chemotherapy.

Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.

D. Livermore, Y. Yang, 1989, The Journal of antimicrobial chemotherapy.

Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia

D. Livermore, A. Shibl, N. Elkhizzi, 2012, Journal of chemotherapy.

Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.

Ronald N. Jones, M. Castanheira, D. Livermore, 2009, Diagnostic microbiology and infectious disease.

Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss.

N. Woodford, D. Livermore, D. Yong, 2007, International journal of antimicrobial agents.

The impact of carbapenemases on antimicrobial development and therapy.

D. Livermore, 2002, Current opinion in investigational drugs.

Carbapenemases of Chryseobacterium(Flavobacterium) meningosepticum: Distribution ofblaB and Characterization of a Novel Metallo-β-Lactamase Gene, blaB3, in the Type Strain, NCTC 10016

N. Woodford, D. Livermore, G. Babini, 2000, Antimicrobial Agents and Chemotherapy.

Outbreak of Carbapenem-Resistant Acinetobacter baumannii Producing the OXA-23 Enzyme in Curitiba, Brazil

N. Woodford, D. Livermore, J. Coelho, 2003, Journal of Clinical Microbiology.

Properties and potential of ertapenem.

D. Livermore, G. Scott, A. Sefton, 2003, The Journal of antimicrobial chemotherapy.

SHV-14, a Novel β-Lactamase Variant inKlebsiella pneumoniae Isolates from Nijmegen, The Netherlands

D. Livermore, L. Hall, M. Yuan, 2001, Antimicrobial Agents and Chemotherapy.

Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa

D. Livermore, 1992, Antimicrobial Agents and Chemotherapy.

Evaluation of multiplex tandem PCR (MT-PCR) assays for the detection of bacterial resistance genes among Enterobacteriaceae in clinical urines

J. Wain, J. O’Grady, D. Livermore, 2018, The Journal of antimicrobial chemotherapy.

Plasmids Imparting Sulfonamide Resistance in Escherichia coli: Implications for Persistence

D. Livermore, L. Hall, D. Bean, 2008, Antimicrobial Agents and Chemotherapy.

Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria.

N. Woodford, D. Livermore, M. Warner, 2014, The Journal of antimicrobial chemotherapy.

Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae.

D. Livermore, D M Livermore, L. Hall, 1998, The Journal of antimicrobial chemotherapy.

Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.

D. Livermore, M. Warner, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

Mechanisms of resistance to β-lactam antibiotics

D. Livermore, 1991 .

Antibiotic resistance in staphylococci.

D. Livermore, D M Livermore, 2000, International journal of antimicrobial agents.

Interactions of β-Lactamases with Sanfetrinem (GV 104326) Compared to Those with Imipenem and with Oral β-Lactams

D. Livermore, G. Babini, M. Yuan, 1998, Antimicrobial Agents and Chemotherapy.

Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS).

B. Cookson, D. Livermore, A. Johnson, 2001, The Journal of antimicrobial chemotherapy.

Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus.

B. Cookson, D. Livermore, A. Johnson, 2000, The Journal of antimicrobial chemotherapy.

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

D. Livermore, D. James, A. Johnson, 2000, The Journal of antimicrobial chemotherapy.

The 2018 Garrod Lecture: Preparing for the Black Swans of resistance

D. Livermore, 2018, The Journal of antimicrobial chemotherapy.

Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06.

D. Livermore, R. Reynolds, R. George, 2008, The Journal of antimicrobial chemotherapy.

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†

C. Mcnulty, D. Livermore, J. Otter, 2018, The Journal of antimicrobial chemotherapy.

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

D. Livermore, David M Livermore, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland.

M. Kaufmann, N. Woodford, D. Livermore, 2006, The Journal of antimicrobial chemotherapy.

Epidemiology of antibiotic resistance

D. Livermore, D. M. Livermore, 2000, Intensive Care Medicine.

Has the era of untreatable infections arrived?

D. Livermore, 2009, The Journal of antimicrobial chemotherapy.

Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms.

D. Livermore, M. Warner, S. Mushtaq, 2009, The Journal of antimicrobial chemotherapy.

In vitro activities of Ro 17-2301 and aztreonam compared with those of other new beta-lactam antibiotics against clinical isolates of Pseudomonas aeruginosa

D. Livermore, P. Chau, W. Ng, 1985, Antimicrobial Agents and Chemotherapy.

Expression of H1 outer-membrane protein of Pseudomonas aeruginosa in relation to sensitivity to EDTA and polymyxin B.

D. Livermore, R. Williams, A. Said, 1987, Journal of medical microbiology.

Increasing prevalence of methicillin resistance amongst Staphylococcus aureus blood culture isolates.

D. Livermore, D. James, A. Johnson, 1999, Journal of Antimicrobial Chemotherapy.

Hydrolytic model for cefotaxime and ceftriaxone resistance in beta-lactamase-derepressed Enterobacter cloacae.

D. Livermore, K. Davy, S. J. Riddle, 1986, The Journal of infectious diseases.

Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa.

D. Livermore, L. Hall, F. Danel, 1999, The Journal of antimicrobial chemotherapy.

Original articles Laboratory mutants of OXA-10 ‚-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa

D. Livermore, L. Hall, F. Danel, 1999 .

Current Epidemiology and Growing Resistance of Gram-Negative Pathogens

D. Livermore, 2012, The Korean journal of internal medicine.

Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.

D. Livermore, M. Warner, S. Mushtaq, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Pseudomonas aeruginosa beta-lactamase as a defence against azlocillin, mezlocillin and piperacillin.

D. Livermore, K. Davy, J. Jacobs, 1984, The Journal of antimicrobial chemotherapy.

National survey of antibiotic resistance in Pseudomonas aeruginosa.

J. Williams, D. Livermore, R. Williams, 1984, The Journal of antimicrobial chemotherapy.

Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia

Z. Memish, D. Livermore, S. Yezli, 2012, Journal of chemotherapy.

Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods

D. Livermore, 1987, European Journal of Clinical Microbiology.

Beta-lactamase-mediated resistance and opportunities for its control.

D. Livermore, D M Livermore, 1998, The Journal of antimicrobial chemotherapy.

Comparative in-vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin.

D. Livermore, S. Yeo, 1994, The Journal of antimicrobial chemotherapy.

Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests.

H Mittermayer, R Canton, F. Baquero, 2002, The Journal of antimicrobial chemotherapy.

Complexity and Diversity of Klebsiella pneumoniae Strains with Extended-Spectrum β-Lactamases Isolated in 1994 and 1996 at a Teaching Hospital in Durban, South Africa

D. Livermore, S. Essack, Lucinda M. C. Hall, 2001, Antimicrobial Agents and Chemotherapy.

Increasing Hospitalizations and General Practice Prescriptions for Community-onset Staphylococcal Disease, England

I. Petersen, D. Livermore, G. Duckworth, 2008, Emerging Infectious Diseases.

Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England.

Anne M Johnson, I. Petersen, D. Livermore, 2008, Emerging infectious diseases.

Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance

D. Livermore, H. Nikaido, X. Li, 1994, Antimicrobial Agents and Chemotherapy.

Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin

D. Livermore, H. Nikaido, X. Li, 1994, Antimicrobial Agents and Chemotherapy.

Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care.

C. Mcnulty, A. Charlett, D. Livermore, 2006, The Journal of antimicrobial chemotherapy.

Endemic Carbapenem Resistance Associated with OXA-40 Carbapenemase among Acinetobacter baumannii Isolates from a Hospital in Northern Spain

N. Woodford, D. Livermore, K. Towner, 2002, Journal of Clinical Microbiology.

Penicillin-binding protein (PBP) 2 and the post-antibiotic effect of carbapenems.

D. Livermore, P. Majcherczyk, 1990, The Journal of antimicrobial chemotherapy.

Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

N. Woodford, D. Livermore, D. Paterson, 2012, The Journal of antimicrobial chemotherapy.

CTX-M: changing the face of ESBLs in Europe.

N. Woodford, D. Livermore, P. Nordmann, 2006, The Journal of antimicrobial chemotherapy.

Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center

Neil Woodford, John Kornblum, Lynn L. Silver, 2004, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.

D. Livermore, D. James, M. Warner, 2001, The Journal of antimicrobial chemotherapy.

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

N. Woodford, D. Livermore, M. Warner, 2012, The Journal of antimicrobial chemotherapy.

Evaluation of the chromogenic Cica-β-Test for detecting extended-spectrum, AmpC and metallo-β-lactamases

D. Livermore, M. Warner, S. Mushtaq, 2007 .

Evaluation of the chromogenic Cica-beta-Test for detecting extended-spectrum, AmpC and metallo-beta-lactamases.

D. Livermore, M. Warner, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

N. Woodford, D. Livermore, M. Warner, 2016, Antimicrobial Agents and Chemotherapy.

Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.

D. Livermore, D M Livermore, M. Yuan, 1996, The Journal of antimicrobial chemotherapy.

Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.

D. Livermore, G. Bonfiglio, D. Mcvey, 1993, The Journal of antimicrobial chemotherapy.

Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.

D. Livermore, A. MacGowan, R. Reynolds, 2004, The Journal of antimicrobial chemotherapy.

Diverse Sequence Types of Klebsiella pneumoniae Contribute to the Dissemination of blaNDM-1 in India, Sweden, and the United Kingdom

N. Woodford, D. Livermore, M. Toleman, 2012, Antimicrobial Agents and Chemotherapy.

False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins.

N. Woodford, D. Livermore, N. Soares, 2011, The Journal of antimicrobial chemotherapy.

In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase.

N. Woodford, D. Livermore, J. Turton, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

N. Woodford, D. Livermore, M. Warner, 2017, The Journal of antimicrobial chemotherapy.

False-positive extended-spectrum beta-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 beta-lactamase.

D. Livermore, R. Reynolds, M. Warner, 2004, The Journal of antimicrobial chemotherapy.

CTX-M extended-spectrum β-lactamase arrives in the UK

D. Livermore, P. Hawkey, I. Alobwede, 2003 .

CTX-M extended-spectrum beta-lactamase arrives in the UK.

J. Heritage, D. Livermore, P. Hawkey, 2003, The Journal of antimicrobial chemotherapy.

Bases of variation in resistance to beta-lactams in Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase.

D. Livermore, L. Hall, R. Gheorghiu, 1997, The Journal of antimicrobial chemotherapy.

Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes.

D. Livermore, T. Winstanley, D M Livermore, 2001, The Journal of antimicrobial chemotherapy.

Of Pseudomonas, porins, pumps and carbapenems.

D. Livermore, 2001, The Journal of antimicrobial chemotherapy.

Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae.

D. Livermore, H. Chen, 1993, The Journal of antimicrobial chemotherapy.

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe.

V. Miriagou, Y. Carmeli, N. Woodford, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria

N. Woodford, D. Livermore, S. Mushtaq, 2020, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Ceﬁderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria

D. Livermore, S. Mushtaq, A. Vickers, 2020 .

Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.

D. Livermore, S. Mushtaq, 2013, The Journal of antimicrobial chemotherapy.

Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts.

J. Campos, Y. Carmeli, D. Livermore, 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.

D. Livermore, R. Reynolds, R. Hope, 2008, The Journal of antimicrobial chemotherapy.

Effect of media composition on the susceptibility of Xanthomonas mahophilia to β-lactam antibiotics

D. Livermore, G. Bonfiglio, 1991 .

Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases.

D. Livermore, G. Bonfiglio, M. Akova, 1991, Journal of medical microbiology.

Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics.

D. Livermore, G. Bonfiglio, 1991, The Journal of antimicrobial chemotherapy.

OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.

D. Livermore, T. Ida, Kenji. Suzuki, 2015, The Journal of antimicrobial chemotherapy.

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae

N. Woodford, D. Livermore, M. Warner, 2010, Antimicrobial Agents and Chemotherapy.

Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline

D. Livermore, D. Hooper, W. Hope, 2020, Antimicrobial Agents and Chemotherapy.

Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales.

N. Woodford, D. Livermore, S. Mushtaq, 2021, The Journal of antimicrobial chemotherapy.

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae

N. Woodford, D. Livermore, M. Doumith, 2018, The Journal of antimicrobial chemotherapy.

AmpC &bgr;-lactamase induction by avibactam and relebactam

N. Woodford, D. Livermore, S. Mushtaq, 2017, The Journal of antimicrobial chemotherapy.

Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.

D. Livermore, G. Williams, M. Warner, 2010, The Journal of antimicrobial chemotherapy.

Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England

M. Kaufmann, T. Pitt, N. Woodford, 2006, Journal of Clinical Microbiology.

Sulfonamide Resistance in Haemophilus influenzae Mediated by Acquisition of sul2 or a Short Insertion in Chromosomal folP

A. King, D. Livermore, L. Hall, 2002, Antimicrobial Agents and Chemotherapy.

Antibiotic resistance in bacteria from magpies (Pica pica) and rabbits (Oryctolagus cuniculus) from west Wales.

D. Livermore, G. Harrison, S. Projan, 2001, Environmental microbiology.

Effect of subinhibitory concentrations of antibiotics on mutation frequency in Streptococcus pneumoniae.

D. Livermore, S. Henderson-Begg, L. Hall, 2006, The Journal of antimicrobial chemotherapy.

Living with ESBLs

D. Livermore, G. Cornaglia, J. Garau, 2007 .

Extended-spectrum beta-lactamase detected in E coli recovered from calves in Wales.

D. Livermore, E. Liébana, M. Batchelor, 2005, The Veterinary record.

Dissemination of Acinetobacter baumannii Clones with OXA-23 Carbapenemase in Colombian Hospitals

J. Quinn, N. Woodford, D. Livermore, 2007, Antimicrobial Agents and Chemotherapy.

Acinetobacter spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit.

M. Kaufmann, D. Livermore, A. Johnson, 1998, The Journal of antimicrobial chemotherapy.

Worldwide emergence of carbapenem-resistant Acinetobacter spp.

D. Livermore, M. Afzal-Shah, D M Livermore, 1998, The Journal of antimicrobial chemotherapy.

Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized β-Lactamases

D. Livermore, S. Mushtaq, Yigong Ge, 2004, Antimicrobial Agents and Chemotherapy.

High prevalence of acquired quinolone-resistance genes among Enterobacteriaceae from Saudi Arabia with CTX-M-15 β-lactamase.

D. Livermore, A. Shibl, A. Senok, 2012, Diagnostic microbiology and infectious disease.

A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.

Y. Carmeli, D. Livermore, J. Pitout, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.

D. Livermore, T. Cai, S. Mushtaq, 2022, International journal of antimicrobial agents.

Metallo-β-lactamases among Enterobacteriaceae from routine samples in an Italian tertiary-care hospital and long-term care facilities during 2008.

N. Woodford, D. Livermore, R. Pike, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome.

N. Woodford, D. Livermore, M. Ellington, 2010, The Journal of antimicrobial chemotherapy.

beta-Lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance.

D. Livermore, P. Chau, Y. Leung, 1987, The Journal of antimicrobial chemotherapy.

Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens

N. Woodford, D. Livermore, M. Warner, 2018, The Journal of antimicrobial chemotherapy.

Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.

D. Livermore, M. Warner, S. Mushtaq, 2013, The Journal of antimicrobial chemotherapy.

Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6

D. Livermore, P. Nordmann, T. Naas, 1994, Antimicrobial Agents and Chemotherapy.

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

Andrew Jones, R. Beale, D. Livermore, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes.

D. Livermore, S. Mushtaq, T. Ida, 2013, The Journal of antimicrobial chemotherapy.

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.

Neil Woodford, N. Woodford, D. Livermore, 2011, International journal of antimicrobial agents.

Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.

N. Woodford, D. Livermore, S. Mushtaq, 2013, The Journal of antimicrobial chemotherapy.

Activity of ertapenem against Neisseria gonorrhoeae.

D. Livermore, K. Fenton, D. James, 2004, The Journal of antimicrobial chemotherapy.

Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against β-lactam antibiotics

C. Brearley, D. Livermore, S. Carding, 2014, The Journal of antimicrobial chemotherapy.

A novel reverse-line hybridization assay for identifying genotypes of CTX-M-type extended-spectrum beta-lactamases.

D. Livermore, V. Ensor, P. Hawkey, 2007, The Journal of antimicrobial chemotherapy.

Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party.

C. Mcnulty, D. Livermore, J. Otter, 2016, The Journal of hospital infection.

Metallo-β-lactamases among Enterobacteriaceae from routine samples in an Italian tertiary-care hospital and long-term care facilities during 2008: Metallo-β-lactamases among Enterobacteriaceae from routine samples

N. Woodford, D. Livermore, R. Pike, 2011 .

Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria.

N. Woodford, D. Livermore, S. Maggi, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Determinants of the activity of beta-lactamase inhibitor combinations.

D. Livermore, 1993, The Journal of antimicrobial chemotherapy.

Radiolabelling of penicillin-binding proteins (PBPs) in intact Pseudomonas aeruginosa cells: consequences of beta-lactamase activity by PBP-5.

D. Livermore, 1987, The Journal of antimicrobial chemotherapy.

Brief reports Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina

D. Livermore, M. Afzal-Shah, H. Villar, 1999 .

Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina.

D. Livermore, M. Afzal-Shah, H. Villar, 1999, The Journal of antimicrobial chemotherapy.

In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.

D. Livermore, H. Chen, 1994, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

D. Livermore, M. Warner, S. Mushtaq, 2009, International journal of antimicrobial agents.

Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group.

D. Livermore, J. Nickel, T. B. Bjerklund Johansen, 2021, European urology focus.

Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.

D. Livermore, M. Warner, Alan P. Johnson, 2004, The Journal of antimicrobial chemotherapy.

The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii.

M. Kaufmann, T. Pitt, N. Woodford, 2006, FEMS microbiology letters.

Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.

D. Livermore, B. Oppenheim, P. Skepastianos, 1988, The Journal of antimicrobial chemotherapy.

Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water.

N. Woodford, D. Livermore, N. Murphy, 2011, The Journal of antimicrobial chemotherapy.

Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.

D. Livermore, A. Johnson, M. Warner, 2000, The Journal of antimicrobial chemotherapy.

In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.

D. Livermore, M. Warner, Alan P. Johnson, 2002, The Journal of antimicrobial chemotherapy.

Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000

D. Livermore, R. George, D. James, 2001, BMJ : British Medical Journal.

In-vitro activity of MK0787 (N-formimidoyl thienamycin) against Pseudomonas aeruginosa and other Gram-negative organisms and its stability to their beta-lactamases.

J. Williams, D. Livermore, R. Williams, 1981, The Journal of antimicrobial chemotherapy.

β-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to β-lactamase inhibitor combinations

D. Livermore, G. Bonfiglio, 1994 .

Kucers' The use of antibiotics

D. Livermore, 2011 .

Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum beta-lactamases in the UK.

N. Woodford, D. Livermore, M. Ellington, 2007, The Journal of antimicrobial chemotherapy.

OXA-1 &bgr;-lactamase and non-susceptibility to penicillin/&bgr;-lactamase inhibitor combinations among ESBL-producing Escherichia coli

N. Woodford, D. Livermore, K. Hopkins, 2018, The Journal of antimicrobial chemotherapy.

PSEUDOMONAS AERUGINOSA ISOLATES WITH MODIFIED BETA-LACTAMASE INDUCIBILITY: EFFECTS ON BETA-LACTAM SENSITIVITY

D. Livermore, J. Williams, R. Williams, 1982, The Lancet.

Mechanisms by which imipenem may overcome resistance in gram-negative bacilli.

D. Livermore, R. Williams, Y. Yang, 1986, The Journal of antimicrobial chemotherapy.

In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.

J. Williams, D. Livermore, R. Williams, 1981, The Journal of antimicrobial chemotherapy.

Comparison of the β-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa

J. Williams, D. Livermore, RosamundJ. Williams, 1981 .

Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance

D. Livermore, Tom A Fowler, S. Davies, 2013, The Lancet.

Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection

Gemma L. Kay, J. Wain, J. O’Grady, 2019, Nature Biotechnology.

Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents.

D. Livermore, D. James, A. Johnson, 2003, The Journal of hospital infection.

Antibiotic resistance: location, location, location.

D. Livermore, A. Pearson, D M Livermore, 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The role of ISAba1in expression of OXA carbapenemase genes inAcinetobacterbaumannii

M. Kaufmann, T. Pitt, N. Woodford, 2006 .

Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.

N. Woodford, D. Livermore, R. Hill, 2007, International journal of antimicrobial agents.

First isolation of a CTX-M-3 beta-lactamase producer in the United Kingdom.

N. Woodford, D. Livermore, T. Winstanley, 2004, International journal of antimicrobial agents.

Antibiotic resistance during and beyond COVID-19

D. Livermore, 2021, JAC-antimicrobial resistance.

Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK.

N. Woodford, D. Livermore, R. Pike, 2012, The Journal of antimicrobial chemotherapy.

Comparison of BD Phoenix, Vitek 2, and MicroScan Automated Systems for Detection and Inference of Mechanisms Responsible for Carbapenem Resistance in Enterobacteriaceae

Neil Woodford, N. Woodford, D. Livermore, 2010, Journal of Clinical Microbiology.

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

N Woodford, N. Woodford, D. Livermore, 2011, The Journal of antimicrobial chemotherapy.

Dissemination of pCT-Like IncK Plasmids Harboring CTX-M-14 Extended-Spectrum β-Lactamase among Clinical Escherichia coli Isolates in the United Kingdom

N. Woodford, D. Livermore, L. Piddock, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of Antibiotics Alone and in Combination against Brucella melitensis at Neutral and Acidic pHs

D. Livermore, M. Akova, T. Kocagöz, 1999, Antimicrobial Agents and Chemotherapy.

Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.

N. Woodford, D. Livermore, S. Mushtaq, 2021, International journal of antimicrobial agents.

Defining an extended-spectrum beta-lactamase.

D. Livermore, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales

N. Woodford, D. Livermore, S. Mushtaq, 2022, Journal of Antimicrobial Chemotherapy.

In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.

A. Charlett, D. Livermore, D. James, 2003, International Journal of Antimicrobial Agents.

Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.

D. Livermore, L. Hall, G. Babini, 2003, The Journal of antimicrobial chemotherapy.

Determinants of the activity of β-lactamase inhibitor combinations

D. Livermore, 1993 .

New Delhi metallo-β-lactamase 1 – Authors' reply

N. Woodford, D. Livermore, M. Toleman, 2010 .

Characterization of b -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline 1 avibactam (NXL104)

N. Woodford, D. Livermore, M. Warner, 2012 .

Cephalosporin resistance in Pseudomonas aeruginosa, with special reference to the proposed trapping of antibiotics by beta-lactamase.

J. Williams, D. Livermore, K. Davy, 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

Mechanisms of beta-lactam resistance in British isolates of Pseudomonas aeruginosa.

J. Williams, D. Livermore, R. Williams, 1984, Journal of medical microbiology.

Inoculum effects on Etests and agar dilution minimum inhibitory concentrations. Piperacillin and piperacillin-tazobactam against Staphylococcus aureus.

D. Livermore, G. Bonfiglio, 1994, Diagnostic microbiology and infectious disease.

Clavulanate and beta-lactamase induction.

D. Livermore, M. Akova, Y. Yang, 1989, The Journal of antimicrobial chemotherapy.

Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.

N. Woodford, D. Livermore, S. Mushtaq, 2022, The Journal of antimicrobial chemotherapy.

Can β‐lactams be re‐engineered to beat MRSA?

D. Livermore, 2006 .

Detection of CTX-M-15 extended-spectrum β-lactamase in the United Kingdom

N. Woodford, D. Livermore, S. Mushtaq, 2003 .

Are resistance rates among bloodstream isolates a good proxy for other infections? Analysis from the BSAC Resistance Surveillance Programme.

D. Livermore, R. Reynolds, S. Mushtaq, 2021, The Journal of antimicrobial chemotherapy.

Revolutionising Bacteriology to Improve Treatment Outcomes and Antibiotic Stewardship

J. Wain, D. Livermore, David M Livermore, 2013, Infection & chemotherapy.

Rapid and Point-of-Care Testing in Respiratory Tract Infections: An Antibiotic Guardian?

J. O’Grady, V. Gant, D. Livermore, 2020, ACS pharmacology & translational science.

Evolution of β-lactamase inhibitors

D. Livermore, 1994, Intensive Care Medicine.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with 1 Cefepime in an In Vitro Infection Model 2 3 Running title : PK-PD of Tazobactam

D. Livermore, J. McCauley, S. Bhavnani, 2017 .

contributing factor to beta-lactam resistance. Pseudomonas aeruginosa: active efflux as a Role of efflux pump(s) in intrinsic resistance of

D. Livermore, H. Nikaido, 2013 .

Susceptibility of Klebsiella pneumoniae Isolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates

N. Woodford, D. Livermore, M. Hackel, 2011, Antimicrobial Agents and Chemotherapy.

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

N. Woodford, D. Livermore, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

Carbapenemases: a problem in waiting?

N. Woodford, D. Livermore, 2000, Current opinion in microbiology.

Mechanisms of resistance to beta-lactam antibiotics.

D. Livermore, 1991, Scandinavian journal of infectious diseases. Supplementum.

Characterization of an LysR family protein, SmeR from Serratia marcescens S6, its effect on expression of the carbapenem-hydrolyzing beta-lactamase Sme-1, and comparison of this regulator with other beta-lactamase regulators

D. Livermore, P. Nordmann, T. Naas, 1995, Antimicrobial agents and chemotherapy.

Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.

D. Livermore, M. E. Ward, M. Warner, 2005, Journal of Antimicrobial Chemotherapy.

Minimising antibiotic resistance.

D. Livermore, David M Livermore, 2005, The Lancet. Infectious diseases.

Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases.

N. Woodford, D. Livermore, S. Mushtaq, 2020, The Journal of antimicrobial chemotherapy.

OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.

D. Livermore, L. Hall, D. Gur, 1995, Antimicrobial agents and chemotherapy.

Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06.

D. Livermore, R. Reynolds, R. Hope, 2008, The Journal of antimicrobial chemotherapy.

Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure.

D. Livermore, P. Bennett, L. Hall, 2004, The Journal of antimicrobial chemotherapy.

Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams.

D. Livermore, P. J. Wu, 1990, The Journal of antimicrobial chemotherapy.

Chromosomal beta-lactamase expression and resistance to beta-lactam antibiotics in Proteus vulgaris and Morganella morganii

D. Livermore, Y. Yang, 1988, Antimicrobial Agents and Chemotherapy.

, in the Type Strain , NCTC 10016 , blaB 3-Lactamase Gene , β a Novel Metallo-and Characterization of blaB Distribution of : meningosepticum ) Flavobacterium ( Chryseobacterium Carbapenemases

N. Woodford, D. Livermore, G. Babini, 2000 .

Beta-lactamase inhibitors: agents to overcome bacterial resistance.

D. Livermore, R. Micetich, O. Phillips, 1998, Current medicinal chemistry.

beta-Lactamases- the Threat Renews.

D. Livermore, 2009, Current protein and peptide science.

Prevalence and antimicrobial resistance among Gram-negative pathogens in Saudi Arabia

Z. Memish, D. Livermore, S. Yezli, 2014, Journal of chemotherapy.

Complete nucleotide sequence of the IncN plasmid pKOX105 encoding VIM-1, QnrS1 and SHV-12 proteins in Enterobacteriaceae from Bolzano, Italy compared with IncN plasmids encoding KPC enzymes in the USA.

N. Woodford, D. Livermore, A. Carattoli, 2010, The Journal of antimicrobial chemotherapy.

National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia

Z. Memish, D. Livermore, A. Shibl, 2014, Journal of chemotherapy.

Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom.

N. Woodford, D. Livermore, M. Ellington, 2006, The Journal of antimicrobial chemotherapy.

Chromosomal beta-lactamase expression and antibiotic resistance in Enterobacter cloacae.

D. Livermore, R. Williams, Y. Yang, 1988, Journal of medical microbiology.

COVID-19 vaccination and HIV-1 acquisition

D. Livermore, H. Ertl, C. Czerkinsky, 2022, The Lancet.

Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England.

D. Livermore, M. Warner, Alan P. Johnson, 2006, The Journal of antimicrobial chemotherapy.

Unusual tazobactam-sensitive AmpC-lactamase from two Escherichia coli isolates

D. Livermore, G. Babini, S. Munro, 1998 .

Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.

D. Livermore, G. Babini, S. Munro, 1998, The Journal of antimicrobial chemotherapy.

Plasmid-mediated production of class I (AmpC) beta-lactamase by two Klebsiella pneumoniae isolates from the UK.

D. Livermore, S. Mehtar, F. Danel, 1995, The Journal of antimicrobial chemotherapy.

Emergence of Enterobacteriaceae Isolates Producing CTX-M Extended-Spectrum β-Lactamase in Austria

N. Woodford, D. Livermore, G. Feierl, 2006, Antimicrobial Agents and Chemotherapy.

Real-time PCR for detection of the O25b-ST131 clone of Escherichia coli and its CTX-M-15-like extended-spectrum beta-lactamases.

Neil Woodford, Russell Hope, E. Denamur, 2010, International journal of antimicrobial agents.

Impact of a clonal outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK.

D. Webster, B. Cookson, D. Livermore, 2011, The Journal of antimicrobial chemotherapy.

Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum beta-lactamases in nursing homes in Belfast, UK.

N. Woodford, D. Livermore, A. Loughrey, 2011, Journal of Antimicrobial Chemotherapy.

Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.

D. Livermore, M. Warner, S. Mushtaq, 2011, International journal of antimicrobial agents.

Typing and epidemiological surveillance show that UK bloodstream Escherichia coli with extended-spectrum β-lactamases correspond to human gut strains, but not those from dinner

N. Woodford, D. Livermore, K. Hopkins, 2019 .

OXA-li, anExtended-Spectrum Variant ofOXA-10(PSE-2) ,-Lactamase fromPseudomonas aeruginosa

D. Livermore, M. Akova, L. Hall, 1993 .

Diversity of klebsiellae with extended-spectrum beta-lactamases at a Turkish university hospital.

T. Pitt, D. Livermore, D. Gür, 1992, The Journal of hospital infection.

Of stewardship, motherhood and apple pie.

D. Livermore, 2014, International journal of antimicrobial agents.

Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey.

D. Livermore, L. Hall, L. Mulazımoglu, 1995, Journal of medical microbiology.

Early onset Morganella morganii sepsis in a newborn infant with emergence of cephalosporin resistance caused by depression of AMPC beta-lactamase production..

D. Livermore, S. Kempley, A. Sinha, 2006, The Pediatric infectious disease journal.

Nationwide Survey of CTX-M-Type Extended-Spectrum β-Lactamases among Klebsiella pneumoniae Isolates in Slovenian Hospitals

K. Seme, N. Woodford, D. Livermore, 2008, Antimicrobial Agents and Chemotherapy.

Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.

D. Livermore, G. Babini, M. Yuan, 1998, Antimicrobial agents and chemotherapy.

Acquired carbapenemases.

D. Livermore, D M Livermore, 1997, The Journal of antimicrobial chemotherapy.

Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae

N. Woodford, D. Livermore, A. Haldimann, 2019, The Journal of antimicrobial chemotherapy.

Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.

M. Kaufmann, S. Gaskin, T. Pitt, 1996, Journal of medical microbiology.

Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.

N. Woodford, D. Livermore, D. James, 2015, The Journal of antimicrobial chemotherapy.

Overstretching the mutant prevention concentration.

D. Livermore, 2003, The Journal of antimicrobial chemotherapy.

Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.

D. Livermore, G. Babini, 2000, The Journal of antimicrobial chemotherapy.

Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia.

Z. Memish, D. Livermore, A. Shibl, 2012, The Journal of antimicrobial chemotherapy.

Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters.

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Rapid Identification of Major Escherichia coli Sequence Types Causing Urinary Tract and Bloodstream Infections

J. Wain, N. Woodford, D. Livermore, 2014, Journal of Clinical Microbiology.

Which cephalosporin for gonorrhoea?

D. Livermore, K. Fenton, J. Mouton, 2004, Sexually Transmitted Infections.

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

D. Livermore, T. Nichols, J. Mouton, 2010, The Journal of antimicrobial chemotherapy.

Rapid Diagnosis of Lower Respiratory Infection using Nanopore-based Clinical Metagenomics

Richard M. Leggett, Justin O’Grady, Gemma L. Kay, 2018, bioRxiv.

Persistence of Klebsiella pneumoniae clones with OXA-48 or NDM carbapenemases causing bacteraemias in a Riyadh hospital.

D. Livermore, J. Turton, A. Shibl, 2013, Diagnostic microbiology and infectious disease.

Future directions with daptomycin.

D. Livermore, 2008, The Journal of antimicrobial chemotherapy.

Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom.

M. Kaufmann, N. Woodford, D. Livermore, 2008, The Journal of antimicrobial chemotherapy.

Resistance to trimethoprim in Haemophilus influenzae

D. Livermore, Y. Hu, M. Powell, 1991, Infection.

Intensivists’ beliefs about rapid multiplex molecular diagnostic testing and its potential role in improving prescribing decisions and antimicrobial stewardship: a qualitative study

V. Gant, D. Brealey, S. Brett, 2021, Antimicrobial Resistance & Infection Control.

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial

D. Thickett, D. Livermore, W. Fraser, 2018, Trials.

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole ( EME-TIPAC )

D. Thickett, D. Livermore, W. Fraser, 2018 .

Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria

J. Nieman, S. Cusack, D. Livermore, 2013, Antimicrobial Agents and Chemotherapy.

INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care—study protocol for a multicentre randomised controlled trial

J. O’Grady, V. Gant, D. Brealey, 2021, Trials.

Susceptibility of Moraxella catarrhalis isolates to β-lactam antibiotics in relation to β-lactamase pattern

D. Livermore, C. Fung, S. Yeo, 1994 .

Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007.

D. Livermore, D. Farrell, R. Reynolds, 2008, The Journal of antimicrobial chemotherapy.

A review of health economic models exploring and evaluating treatment and management of Hospital-Acquired Pneumonia (HAP) and Ventilator Associated pneumonia (VAP).

D. Livermore, J. Craig, D. Turner, 2020, The Journal of hospital infection.

In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases.

D. Livermore, J. Williams, J. Williams, 1981, The Journal of antimicrobial chemotherapy.

Possible contamination of organ preservation fluid with Bacillus cereus: the United Kingdom response.

N. Woodford, D. Livermore, M. Zambon, 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Narrative review of primary care point-of-care testing (POCT) and antibacterial use in respiratory tract infection (RTI)

Cliodna McNulty, Michael Moore, C. Mcnulty, 2015, BMJ Open Respiratory Research.

Detection of Oxazolidinone-Resistant Enterococcus faecalis and Enterococcus faecium Strains by Real-Time PCR and PCR-Restriction Fragment Length Polymorphism Analysis

N. Woodford, D. Livermore, C. Auckland, 2002, Journal of Clinical Microbiology.

In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.

D. Livermore, R. Hope, Aiysha Chaudhry, 2013, International journal of antimicrobial agents.

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

N. Woodford, D. Livermore, M. Warner, 2009, The Journal of antimicrobial chemotherapy.

In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp.

N. Woodford, D. Livermore, R. Hill, 2007, The Journal of antimicrobial chemotherapy.

Emerging Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Two Austrian Patients in the Same Intensive Care Unit

M. Kaufmann, N. Woodford, D. Livermore, 2002, European Journal of Clinical Microbiology and Infectious Diseases.

Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.

D. Livermore, M. Warner, Alan P. Johnson, 2004, The Journal of antimicrobial chemotherapy.

Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data.

D. Livermore, S. Mushtaq, C. Horner, 2020, The Journal of antimicrobial chemotherapy.

Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study

A. Oliver, M. Delmée, D. Livermore, 2017, The Journal of antimicrobial chemotherapy.

Activity of Ertapenem (MK-0826) versusEnterobacteriaceae with Potent β-Lactamases

D. Livermore, M. Warner, M. Carter, 2001, Antimicrobial Agents and Chemotherapy.

Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.

D. Livermore, E. Fagan, D. James, 2006, The Journal of antimicrobial chemotherapy.

Antimicrobial use and microbiological testing in district general hospital ICUs of the Veneto region of north-east Italy

D. Livermore, C. Romualdi, M. Menegozzo, 2016, European Journal of Clinical Microbiology & Infectious Diseases.

Decreased susceptibility to cephalosporins among gonococci? Authors' reply.

D. Livermore, C. Lowndes, K. Town, 2014, The Lancet. Infectious diseases.

What's left in the cupboard? Older antimicrobials for treating gonorrhoea.

N. Woodford, D. Livermore, M. Cole, 2021, The Journal of antimicrobial chemotherapy.

Class D β-Lactamases

M. Page, D. Livermore, F. Danel, 2007 .

Evidence of dimerisation among class D β-lactamases: kinetics of OXA-14 β-lactamase

J. Frère, D. Livermore, F. Danel, 2001 .

Can beta-lactams be re-engineered to beat MRSA?

D. Livermore, 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci

S. North, N. Woodford, D. Livermore, 2007, Antimicrobial Agents and Chemotherapy.

SHV-13, a Novel Extended-Spectrum β-Lactamase, in Klebsiella pneumoniae Isolates from Patients in an Intensive Care Unit in Amsterdam

D. Livermore, C. Vandenbroucke-Grauls, L. Hall, 2000, Antimicrobial Agents and Chemotherapy.

KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region.

N. Woodford, D. Livermore, K. Hopkins, 2016, The Journal of antimicrobial chemotherapy.

Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its “Sell-By Date” in an Era of New Antibiotics and Regional Carbapenemase Epidemiology

D. Livermore, K. Hopkins, D. Nicolau, 2020 .

'CRE, CRO, CPE and CPO': terminology past its 'sell-by-date' in an era of new antibiotics and regional carbapenemase epidemiology.

D. Livermore, K. Hopkins, D. Nicolau, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.

J. Wain, N. Woodford, D. Livermore, 2014, International journal of antimicrobial agents.

Permeation of β-Lactam Antibiotics into Escherichia coli, Pseudomonas aeruginosa, and Other Gram-Negative Bacteria

D. Livermore, 1988 .

Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework

V. Gant, D. Brealey, S. Brett, 2021, BMJ Quality & Safety.

Enhanced surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland

A. Charlett, B. Cookson, D. Livermore, 2009, Archives of Disease in Childhood.

Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpoints.

D. Livermore, D. James, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

ISEcp1-mediated transposition of linked blaCTX-M-3 and blaTEM-1b from the IncI1 plasmid pEK204 found in clinical isolates of Escherichia coli from Belfast, UK.

N. Woodford, D. Livermore, M. Doumith, 2011, The Journal of antimicrobial chemotherapy.

AmpC induction by ceftaroline.

D. Livermore, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph

D. Livermore, 2009 .

Back to the Future: Can Vaccines Win the Long-Term Fight Against COVID-19?

D. Livermore, H. Ertl, S. Currie, 2022, Frontiers in Public Health.

Reaction products of chloramphenicol acetyltransferases from enterobacteria and Haemophilus influenzae.

D. Livermore, K. Davy, M. Powell, 1989, The Journal of antimicrobial chemotherapy.

Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.

D. Livermore, A. Johnson, M. Warner, 2001, International Journal of Antimicrobial Agents.

Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England.

D. Livermore, R. George, A. Johnson, 2003, The Journal of antimicrobial chemotherapy.

Selection and transformation of non-β-lactamase-mediated insusceptibility of β-lactams in Haemophilus influenzae: lack of cross-resistance between carbapenems and other agents

D. Livermore, M. Powell, 1990 .

Activity of mecillinam against ESBL producers in vitro.

N. Woodford, D. Livermore, M. Warner, 2006, The Journal of antimicrobial chemotherapy.

Activity of temocillin and other penicillins against beta-lactamase-inducible and -stably derepressed enterobacteria.

D. Livermore, Y. Yang, 1988, The Journal of antimicrobial chemotherapy.

P1025 Isolation of quinolone-resistant CTX-M-producing Escherichia coli from raw chicken meat sold in retail outlets in the West Midlands, UK

N. Woodford, D. Livermore, K. Nye, 2007 .

Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014

N. Woodford, D. Livermore, R. Hill, 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms.

D. Livermore, M. Warner, S. Mushtaq, 2010, The Journal of antimicrobial chemotherapy.

Interactions of meropenem with Class I chromosomal β-lactamases

D. Livermore, Youjun Yang, 1989 .

Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'.

D. Livermore, M. Warner, S. Mushtaq, 2001, Journal of Antimicrobial Chemotherapy.

Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical.

D. Livermore, I. Gyssens, C. Viscoli, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.

T. Pitt, N. Woodford, D. Livermore, 2006, The Journal of antimicrobial chemotherapy.

Multidrug-resistant (MDR) Gram-negative bacteria information leaflets.

D. Livermore, J. Otter, C. Mcnulty, 2016, The Journal of hospital infection.

Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .

D. Livermore, P. Seetulsingh, 1991, The Journal of antimicrobial chemotherapy.

β -Lactamases- the Threat Renews

D. Livermore, 2009 .

P864 Complete nucleotide sequence of pEK499, a multidrug-resistance plasmid from the UK's most prevalent Escherichia coli strain with CTX-M-15 β-lactamase

N. Woodford, D. Livermore, M. Ellington, 2007 .

Low in vitro selection frequencies of enterococcal and staphylococcal mutants resistant to the oxazolidinone AZD2563.

N. Woodford, D. Livermore, Alan P. Johnson, 2004, International journal of antimicrobial agents.

Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland.

N. Woodford, D. Livermore, J. Turton, 2003, The Journal of antimicrobial chemotherapy.

Effects of β-lactamase induciblilty and derepression on the activity of cefepime and cefpirome against Gram-negative bacteria

D. Livermore, H. Chen, 1993 .

CLASS I β-LACTAMASE EXPRESSION IN PSEUDOMONAS AERUGINOSA AND CEPHALOSPORIN RESISTANCE

D. Livermore, J. Selkon, R. Hewinson, 1986, The Lancet.

Two cases of import ation of New Delhi Metallo-β-lactamase 1 into Northern Ireland

D. Livermore, D. Kealey, S. Christie, 2012, Ulster medical journal.

Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria

Y. Barenholz, D. Livermore, S. Mushtaq, 2021, Pharmaceutics.

β-Lactamases: quantity and resistance

D. Livermore, 1997 .

Role of beta-lactamase and impermeability in the resistance of Pseudomonas aeruginosa.

D. Livermore, 1989, Antibiotics and Chemotherapy.

Behaviour of TEM-1 beta-lactamase as a resistance mechanism to ampicillin, mezlocillin and azlocillin in Escherichia coli.

D. Livermore, F. Moosdeen, M. A. Lindridge, 1986, The Journal of antimicrobial chemotherapy.

Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance.

D. Livermore, H. Chen, 1994, The Journal of antimicrobial chemotherapy.

Activity of sulbactam combinations against Escherichia coli isolates with known amounts of TEM-1 beta-lactamase.

D. Livermore, 1992, The Journal of antimicrobial chemotherapy.

Antibacterial usage in English NHS hospitals as part of a national Antimicrobial Stewardship Programme.

D. Livermore, J. Cooke, M. Sharland, 2014, Public health.

Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci.

D. Livermore, M. Warner, S. Mushtaq, 2014, International journal of antimicrobial agents.

Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae.

D. Livermore, E. Fagan, M. Warner, 2006, The Journal of antimicrobial chemotherapy.

PTX 2416, a dihydroxypyridone monobactam, vs Pseudomonas aeruginosa strains with characterised resistances

D. Livermore, S. Mushtaq, 2003 .

Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test

J. O’Grady, V. Gant, D. Brealey, 2020, medRxiv.

Fusidic-acid use and resistance

D. Livermore, G. Duckworth, D. James, 2002, The Lancet.

Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors.

R. Pebody, D. Livermore, G. Duckworth, 2006, International journal of antimicrobial agents.

Carbapenem-Resistant Klebsiella pneumoniae in Singapore Producing IMP-1 β-Lactamase and Lacking an Outer Membrane Protein

N. Woodford, D. Livermore, L. Hall, 2001, Antimicrobial Agents and Chemotherapy.

Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to XDR-Pseudomonas aeruginosa

Andrew Jones, R. Beale, D. Livermore, 2019 .

beta-Lactamases: quantity and resistance.

D. Livermore, 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases.

N. Woodford, D. Livermore, K. Hopkins, 2014, The Journal of antimicrobial chemotherapy.

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

N. Woodford, D. Livermore, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

Evaluation of the VITEK 2 AST N-054 test card for the detection of extended-spectrum beta-lactamase production in Escherichia coli with CTX-M phenotypes.

D. Livermore, P. Rooney, R. McMullan, 2008, Journal of Antimicrobial Chemotherapy.

Has the era of untreatable infections arrived?

D. Livermore, 2009, The Journal of antimicrobial chemotherapy.

Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study.

D. Livermore, M. Toleman, T. Walsh, 2011, The Lancet. Infectious diseases.

Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria.

N. Woodford, D. Livermore, S. Maggi, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Plasmids Imparting Sulfonamide Resistance in Escherichia coli: Implications for Persistence

D. Livermore, L. Hall, D. Bean, 2008, Antimicrobial Agents and Chemotherapy.

Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy.

N. Woodford, D. Livermore, M. Doumith, 2008, The Journal of antimicrobial chemotherapy.

Klebsiella pneumoniae isolate from South Africa with multiple TEM, SHV and AmpC beta-lactamases.

D. Livermore, S. Essack, L. Hall, 2004, International Journal of Antimicrobial Agents.

UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone.

M. Kaufmann, N. Woodford, D. Livermore, 2008, The Journal of antimicrobial chemotherapy.

Comparison of BD Phoenix, Vitek 2, and MicroScan Automated Systems for Detection and Inference of Mechanisms Responsible for Carbapenem Resistance in Enterobacteriaceae

N. Woodford, D. Livermore, J. Steer, 2010, Journal of Clinical Microbiology.

National glycopeptide-resistant enterococcal bacteraemia surveillance Working Group report to the Department of Health - August 2004.

B. Cookson, N. Woodford, D. Livermore, 2006, The Journal of hospital infection.

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

D. Livermore, T. Nichols, J. Mouton, 2010, The Journal of antimicrobial chemotherapy.

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

D. Livermore, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System

N. Woodford, D. Livermore, G. Bou, 2011, Antimicrobial Agents and Chemotherapy.

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

N. Woodford, D. Livermore, M. Warner, 2011, The Journal of antimicrobial chemotherapy.

Trends among pathogens reported as causing bacteraemia in England, 2004-2008.

D. Livermore, Alan P. Johnson, E. Sheridan, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, Colombia

M. Kaufmann, D. Livermore, J. Turton, 2004, Journal of Clinical Microbiology.

Are all beta-lactams created equal?

D. Livermore, D M Livermore, 1996, Scandinavian journal of infectious diseases. Supplementum.

Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06.

D. Livermore, R. Reynolds, R. Hope, 2008, The Journal of antimicrobial chemotherapy.

Pseudomonas aeruginosa sequence type 357 with VEB extended-spectrum β-lactamases in the UK: relatedness and resistance.

N. Woodford, D. Livermore, K. Hopkins, 2018, International journal of antimicrobial agents.

Pseudomonas aeruginosa ST 357 with VEB ESBLs in the UK : relatedness and 2 resistance 3 4

N. Woodford, D. Livermore, K. Hopkins, 2018 .

with Activity against Gram-negative Bacteria

J. Nieman, S. Cusack, D. Livermore, 2013 .

Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013.

A. Friedrich, Y. Carmeli, N. Woodford, 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Dissemination of Acinetobacter baumannii Clones with OXA-23 Carbapenemase in Colombian Hospitals

J. Quinn, N. Woodford, D. Livermore, 2007, Antimicrobial Agents and Chemotherapy.

Multiresistant acinetobacter in the UK: how big a threat?

N. Woodford, D. Livermore, J. Turton, 2004, The Journal of hospital infection.